Dr Robert Rifkin discusses treatment resistance in multiple myeloma

0

Robert Rifkin, MD, FACP, medical oncologist and hematologist at Rocky Mountain Cancer Centers, emphasizes the importance of studying treatment-resistant patients with multiple myeloma.

Multiple myeloma has become almost a chronic disease, with prolonged prolonged survival, said Robert Rifkin, MD, FACP, medical oncologist and hematologist at Rocky Mountain Cancer Centers.

Transcription

Can you elaborate on the challenge of treatment resistance in patients with multiple myeloma?

Well, I think what we’ve done over time is myeloma has become almost a chronic disease, because I just told you about extended and extended survival. As a result, I think we probably created some new resistance mechanisms after being exposed to all of these things. If we can use this data as data to research the next lines of therapy and understand the mechanisms of resistance, we will continue to do better.

The other thing that is really starting to show up in multiple myeloma is that we are now able to do tests for minimal residual disease. [MRD]. As we come up with more and more effective therapies, we hope that we can make people negative for MRD at several times and maybe the cake in the sky is if you are negative for MRD for a few. years, you may not need more treatment for myeloma. Because as you all know, myeloma is really a disease of continuous therapy.

Hopefully, using these triple-class refractory patients as a scientific basis, we can come up with better therapies that will make you MRD negative. Additionally, it allows us to model healthcare resource use, quality of life measures, and a variety of other things, which are very important in the real world. So the Connect MM Registry really provides us with a formidable basis to examine these emerging new triple-class refractory patients.

Share.

Comments are closed.